Drug intelligence / Profile preview

VALERGEN-DP + VALERGEN-BT

Development stage: Unknown
Lead developer: BioCen
Modality: Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

VALERGEN-DP + VALERGEN-BT is a combination sublingual allergen immunotherapy (SLIT) vaccine developed by the Centro Nacional de Biopreparados (BioCen) in Cuba. It is specifically designed for the treatment of allergic asthma in adults who exhibit dual sensitization to the house dust mites *Dermatophagoides pteronyssinus* and *Blomia tropicalis*. The vaccine consists of standardized allergen extracts from these two mite species. By administering these allergens sublingually, the therapy aims to induce immunological tolerance, thereby modulating the allergic immune response and reducing the clinical symptoms of asthma. While the individual VALERGEN components are already registered for use, this specific combination represents a new formulation tailored for dually sensitized patients and is currently in Phase 2 clinical development.

Other names: Combined immunotherapy VALERGEN-DP + VALERGEN-BTVALERGEN-DP + VALERGEN-BT (sublingual)

Targets

TCR (T cell antigen receptor complex)IgE (Immunoglobulin E)

Beyond the preview

Go deeper on VALERGEN-DP + VALERGEN-BT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VALERGEN-DP + VALERGEN-BT.

Explore the full profile